WO2001097791A2 - Utilisation d'acides en c4-c10 pour la prévention des infections a bactéries a gram négatif - Google Patents
Utilisation d'acides en c4-c10 pour la prévention des infections a bactéries a gram négatif Download PDFInfo
- Publication number
- WO2001097791A2 WO2001097791A2 PCT/FR2001/001971 FR0101971W WO0197791A2 WO 2001097791 A2 WO2001097791 A2 WO 2001097791A2 FR 0101971 W FR0101971 W FR 0101971W WO 0197791 A2 WO0197791 A2 WO 0197791A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- use according
- sodium
- radical
- salmonella
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the use of C 4 -C ⁇ acids for the prevention of infections with Gram negative bacteria, in particular with Salmonella, both in animals and in humans.
- Salmonella are enteroinvasive bacteria pathogenic for humans and animals.
- iagA Transcription of iagA requires the production of two derepressants, SprA (or HilC or SirC) and HilD, which are encoded by SPI-1 genes and are part of the AraC / XylS family (Eichelberg et al., 1999, Mol. MicrobioL, 1999, 33, 139-152; Schechter et al., Mol. MicrobioL, 1999, 32, 629-642).
- the transcription of iagA is also controlled directly or indirectly by two two-component systems, RcsB-RcsC and PhoP-PhoQ, which are not coded by genes located at centisome 63.
- the RcsB-RcsC system responds to osmolarity (Arricau et al., Mol. MicrobioL, 1998, 29, 835-850) and the Phop-PhoQ system for the concentration of divalent cations such as calcium and magnesium ions (Garcia Véscoci et al., Cell, 1996, 84, 165- 174; Miller et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 5054-5058) of the environmental medium.
- divalent cations such as calcium and magnesium ions
- the PhoP-PhoQ and RcsB-RcsC systems suppress directly or indirectly the expression of iagA.
- the genes coding for the components and targets of the Inv-Spa-Prg secretion apparatus are not expressed, the Salmonella are unable to enter the epithelial cells in culture.
- the PhoP-PhoQ and RcsB-RcsC systems no longer repress the expression of iagA.
- Sip proteins are also synthesized, but they remain stored in the cytoplasmic compartment because the secretion apparatus is inactive.
- the activity of the secretory apparatus will be triggered by contact with the epithelial cell (Galan, 1996).
- the Sip proteins will be secreted and form a translocator, which will be used to inject the effector proteins, including StpA and AvrA, into the cytosol of the target cell.
- These effector proteins then activate different signaling pathways, leading to a variety of cellular responses and ultimately the entry of Salmonella into the cell.
- these two conditions osmolarity and high concentration of divalent cations
- Salmonella is then very greatly reduced (Bajaj et al, Mol. MicrobioL, 1996, 22, 703-714). In fact, Salmonella cultured in a medium with low osmolarity or with a low concentration of divalent cations are incapable of penetrating into the epithelial cells in culture. All the data reported above shows that the expression of the entry phenotype in Salmonella is very finely controlled by regulators acting in cascade (all are probably not identified) depending on the environmental conditions. If one interferes with only one of these regulators, then this should result in a non-invasive phenotype.
- Salmonella therefore always constitutes a major public health problem.
- Epidemiological studies have clearly shown that this resurgence of salmonellosis (except in the case of typhoid fever, which is a strictly human disease) was due to the consumption of animal products contaminated with Salmonella.
- S. enteritidis which has caused a global epidemic.
- the source of contamination by S. enteritidis has been fully identified. These were eggs and egg products.
- lauric acid for example, which is a saturated fatty acid whose chain is formed by 12 carbon atoms, has bactericidal activity in vitro on S. typhi, Vibrio cholerae, and Shigella sonnei at a concentration of 0.25 g / 1.
- caprylic acid has no bacteriostatic or bactericidal effect on Gram-positive or Gram-negative bacteria, while other fatty acids with a more saturated carbon chain long, in particular from 12 carbon atoms such as lauric acid or certain unsaturated fatty acids such as for example linoleic acid and oleic acid, are very effective (Kabara et al., Antimicrob. Agents Chemother, 1972, 2, 23-31).
- fatty acids such as, for example, n-hexanoic, caprylic and decanoic acids exhibit, at acidic pH, bactericidal activity on a wide variety of Gram-positive or negative microorganisms and make it possible to treat different types of 'infections (US patents 4,489,097 and US 4,406,884, patent application EP 0 021 504). These documents specify however that to be effective, these acids must be used at acidic pH to be in the form of free acid.
- bacteriostatic or bactericidal activity of fatty acids is linked to the length of the carbon chain and to the number of unsaturations which it carries, the most important activity being attributed to fatty acids containing at least 12 atoms of carbon and preferably one or two unsaturations.
- a subject of the present invention is therefore the use of an effective amount of at least one compound of formula (I) below:
- R, -COO-R 2 in which: - Ri represents a saturated C 4 -C carbon chain, optionally substituted by one or more hydroxyl or amino functions or by an aromatic ring; - R represents a hydrogen atom; a monovalent alkali metal atom; an alkyl radical; it being understood that when R represents a hydrogen atom and that Ri represents a saturated C 7 carbon chain substituted by an a ine function, then said amine function is not in position 2 or 8; as active ingredient, for the preparation of a pharmaceutical composition having a neutral pH intended to prevent infections with Gram-negative bacteria, in humans or in animals.
- active principle for the preparation of a pharmaceutical composition having a neutral pH intended to prevent infections with Gram negative bacteria and in particular with Salmonella, both in humans and in animals.
- the compounds of formula (I) above can therefore be in the form of an acid, a salt or an ester.
- the inventors have in particular demonstrated that the preventive administration of a composition having a neutral pH and containing at least sodium caprylate to mice subsequently infected with three major Salmonella serotypes makes it possible to considerably reduce the level of splenic colonization by these bacteria. whereas this composition does not exhibit bactericidal activity at such a pH
- the pH of the pharmaceutical composition used is preferably between 6.5 and 7.5 and even more preferably between 7.1 and 7.4.
- a pH value which is particularly well suited to the use in accordance with the invention is between 7.2 and 7.3.
- radical Ri of the compounds of formula (I) represents a carbon chain substituted by a hydroxyl function
- said hydroxyl function is in position 2 when the radical Ri contains from 4 to 6 carbon atoms and in position 2 or 8 when the radical Ri contains from 7 to 9 carbon atoms.
- caprylic acid which corresponds to a compound of formula (I) in which Ri represents a saturated C 7 carbon chain
- Ri represents a saturated C 7 carbon chain
- its derivatives hydroxylated in position 2 or 8 their salts and their esters are particularly preferred.
- caprylic acid used at a neutral pH unexpectedly makes it possible to prevent Salmonella infections, while at such a pH value, this acid does not exhibit any bactericidal activity.
- the alkali metal atoms defined for the radical R are preferably chosen from sodium and potassium.
- the alkyl radicals defined for the radical R are preferably chosen from C ⁇ -C 4 alkyl radicals, among which very particularly preferred are methyl, ethyl and butyl radicals.
- sodium caprylate is used, that is to say a compound of formula (I) in which R [represents a carbon chain saturated with C and R 2 represents an atom of sodium.
- the effective amount of compound (s) of formula (I) preferably corresponds to unit doses of between 20 mM and 200 mM, and even more preferably between 50 mM and 100 mM.
- composition used in accordance with the invention may also contain one or more additional active ingredients.
- the compounds of formula (I) used in accordance with the invention can of course be formulated in an acceptable pharmaceutical vehicle consisting of one or more excipients conventionally used for the preparation of pharmaceutical compositions, such as anti-caking agents, anti- oxidants, colorants, vitamins, mineral salts, taste modifiers, smoothing agents, mounting agents, insulation agents and, in general, any excipient conventionally used in the pharmaceutical industry.
- excipients conventionally used for the preparation of pharmaceutical compositions, such as anti-caking agents, anti- oxidants, colorants, vitamins, mineral salts, taste modifiers, smoothing agents, mounting agents, insulation agents and, in general, any excipient conventionally used in the pharmaceutical industry.
- the pharmaceutical composition used according to the present invention is preferably administered orally and can be in various forms, such as in the form of tablets, capsules, oral suspensions, tablets or in any other form suitable for the mode of administration. oral.
- the pharmaceutical composition used according to the present invention can in particular be added to drinking water and / or to feeds distributed to farm animals (poultry, cattle, pigs, sheep, etc.) so as to reduce the incidence infections with Gram negative bacteria and in particular with Salmonella and limit carriage, and thus reduce the risk of subsequent contamination of humans.
- farm animals proultry, cattle, pigs, sheep, etc.
- the pharmaceutical composition used according to the present invention can also be administered to humans as a preventive medicine in order to reduce the risk of infection in people spending limited stays in a region with a high endemic, in particular of salmonellosis.
- the pharmaceutical composition used according to the present invention can also be used in humans to stop or slow down an epidemic of typhoid fever.
- the invention also comprises other provisions which will emerge from the description which follows, which refers to an example of demonstration of the activity of sodium caprylate in the prevention of salmonellosis in mice (example 1), to a comparative study of the effect of certain fatty acids on the expression of the invasion genes (example 2), as well as to the appended figures, in which:
- FIG. 1 shows the effect of the concentration of Ca 2+ ions on the expression of the iagA '-lacZ, invF'-lacZ and sipB' -lacZ fusions;
- FIG. 2 shows the effect of the concentration of sodium benzoate on the expression of the iagA '-lacZ, invF'-lacZ and sipB' -lacZ fusions
- FIG. 3 shows the effect of the concentration of sodium caprylate on the expression of the iagA '-lacZ, invF'-lacZ and sipB' -lacZ fusions
- TCS trypto-casein-soy broth
- the original standard LB medium contains 170 mM NaCl and 850 ⁇
- the favorable LB medium (high osmolarity and concentration of Ca2 + ions) was defined as being the standard LB medium modified so as to have a final concentration of 300 mM in NaCl and 5 mM in Ca2 +.
- the unfavorable LB medium (high osmolarity and low concentration of Ca2 + ions) has been defined as being the standard LB medium modified so as to have a final concentration of 300 mM in NaCl and is added with 1 mM of ethylene glycol bis- ( ⁇ -aminoethyl ether) -N, N, N ', N'-tetraacetic (EGTA) so as to create a depletion of the medium in divalent cations.
- EGTA ethylene glycol bis- ( ⁇ -aminoethyl ether) -N, N, N ', N'-tetraacetic
- a "Biotype 100” ® plate sold by the company BioMérieux is made up of 100 microcupules. Each microcupule contains a dehydrated carbon substrate, with the exception of the first well which is a control without substrate (the amount of dehydrated substrate per well is not given by the manufacturer).
- the "Biotype 100" ® plate makes it possible to study the nutritional capacity of a bacterial strain on 99 different sources of carbon (auxanogram).
- strain S. typhi Ty267 which is a derivative of the parental strain Ty2 carrying the transcriptional fusion iagA '-lacZcat (Table I), was cultivated in TCS broth for 18 hours at 37 ° C. with shaking (200 turns / min). This culture was then diluted 1/100 in favorable LB medium
- this suspension was used immediately to inoculate the 100 wells of a "Biotype 100" ® plate at the rate of 450 ⁇ l of suspension per well.
- mice By comparing the value of the ⁇ -galactosidase activity measured in a well containing a carbonaceous substrate to that of the control well without substrate, it was thus possible to determine whether a substrate had no effect on, activated or repressed the expression of the iagA '-lacZcat merger.
- I-d Experimental infection of mice
- mice The female C57B1 / 6 mice, 5-6 weeks old, used for this experiment, came from the IFF A-CREDO breeding center (L'Arbresle, France).
- mice had unlimited access to drinking water, the composition of which is given for each experiment.
- mice Seven days after infection (D + 7), the spleens of the mice thus infected were removed and homogenized separately in 1 ml of physiological water containing 0.7% NaCl.
- the number of viable bacteria per spleen was determined by plating dilutions of the homogenate on TCS agar.
- mice were infected as indicated above and the mortality of the animals was recorded for 21 days.
- aromatic acids In addition to caprylic acid, aromatic acids have been studied in order to compare their properties to those of caprylic acid.
- the aromatic acids studied were the following: benzoic acid, phenylacetic acid, 3-phenylpropionic acid and 4-phenylbutyric acid.
- aromatic acids and caprylic acid come from the company Sigma. They were all used in the form of their sodium salt and at a pH between 7.2 and 7.3.
- the aim of this preliminary step was to demonstrate that lacZ transcriptional fusions could be used for the search for environmental conditions repressing the expression of the genes present on the SPI-1 pathogenicity island.
- the S. typhi Ty267, Ty272 and Ty277 strains which carry respectively the iagA '-lacZ, invF'-lacZ and sipB'-lacZ (see Table I) fusions were cultured in favorable LB or unfavorable LB medium.
- the S. typhi strains Ty267 (iagA'-lacZ), Ty272 (invF'-lacZ) and Ty277 (sipB'-lacZ) were cultured in LB medium containing 300 mM NaCl and 5 mM CaCl (representation by a square) or 300 mM NaCl and 1 mM EGTA (representation by a diamond).
- strain S. typhi Ty267 (fusion iagA '-lacZ), suspended in favorable LB medium, was used to inoculate the "Biotype 100" ® plates.
- the ⁇ -galactosidase activity expressed by the iagA '-lacZ fusion was determined for the culture in each well. Compared to the ⁇ -galactosidase activity measured in the control cup without substrate (11250 ⁇ -galactosidase units), no substrate led to an increase in the expression of the iagA '-lacZ fusion.
- the S. typhi Ty267, Ty272 and Ty277 strains were seeded in favorable LB medium and in favorable LB medium containing different concentrations of sodium benzoate or sodium caprylate.
- the square-shaped symbols correspond to the favorable LB medium without the addition of sodium benzoate
- the diamond-shaped symbols correspond to the favorable LB medium with the addition of 5 mM of sodium benzoate
- the circle-shaped symbols correspond to the favorable LB medium with addition of
- the diamond-shaped symbols correspond to the favorable LB medium with the addition of 5 mM sodium caprylate
- the circle-shaped symbols correspond to the favorable LB medium with the addition of
- sodium benzoate or sodium caprylate very strongly represses the expression of the iagA genes, invF and sipB.
- the activity of the fusions is further reduced by 50% compared to the values measured in the favorable LB medium without sodium benzoate. If the favorable LB medium contains 1 mM sodium caprylate, the ⁇ -galactosidase activity expressed by the fusions remains low, of the order of 20% of that measured in the favorable LB medium without sodium caprylate.
- the activity of the iagA '-lacZ fusion measured after 6 hours of culture is very reduced (317 ⁇ 12 ⁇ -galactosidase units ).
- FIG. 4 The results are shown in FIG. 4, in which it can be seen that samples were taken every two hours for the measurement of the OD 6 oo (corresponding to the open symbols) and for the determination of the ⁇ -galactosidase activity (corresponding with solid symbols).
- the strains were cultivated in favorable LB medium without the addition of sodium benzoate or sodium caprylate (symbols in the form of a square in FIG. 4) and in favorable LB medium containing 5 mM of sodium benzoate (diamond shaped symbols in Figure 4) or 5 mM sodium caprylate (circle shaped symbols in Figure 4).
- sodium benzoate and sodium caprylate specifically suppress the expression of the invasion genes of the pathogenicity island SPI-1 in Salmonella.
- strain S. typhi Ty267 (fusion iagA '-lacZ) was seeded in favorable LB medium and in favorable LB medium containing the aromatic acid to be tested at the final concentration of 5 mM.
- the ⁇ -galactosidase activity of the iagA '-lacZ fusion was measured after 6 hours of incubation at 37 ° C. with shaking (200 rpm).
- Sodium 3-phenylpropionate and sodium 4-phenylbutyrate is additive because if each of them is added to the final concentration of 1 mM in the favorable LB medium, the activity of the iagA '-lacZ fusion is strongly repressed (236 ⁇ 10 ⁇ -galactosidase units), whereas this fusion is only partially repressed when the favorable LB medium is supplemented with 1 mM sodium benzoate only (5455 ⁇ 223 ⁇ -galactosidase units).
- the strain S. typhimurium C52 was used to infect C57B1 / 6 mice orally.
- C52 is equal to approximately 4.10 5 bacteria (Coynault et al, Mol. MicrobioL, 1996, 22, 149-160) and the kinetics of colonization of the spleen has been previously reported (Pardon et al, Ann. Inst. Pasteur / MicrobioL, 1986, 137B, 47-60).
- mice were orally infected with 10 8 viable bacteria (250 LD 50 ), the number of viable bacteria was then determined seven days after infection. These results show that the bacterial load in the spleen is reduced significantly significantly (p ⁇ 0.001) in mice having received drinking water having a pH between 7.2 and 7.3 and containing a mixture of 50 mM of sodium benzoate and 50 mM sodium caprylate, provided that treatment is started two days before infection.
- EDTA which like EGTA chelates divalent cations, has been studied in conjunction with the effect of sodium benzoate or sodium caprylate during murine infection with S. typhimurium.
- mice Groups of five C57B1 / 6 mice were infected orally with
- sodium caprylate no longer has a significant protective effect when its concentration is lowered to 5 or 10 mM in drinking water, whatever the infectious dose used.
- mice which had been administered drinking water of pH between 7.2 and 7.3 and containing 50 mM sodium caprylate two days before infection and for the duration of the experiment , was also infected orally with 10 7 bacteria (25 LD 5 o). One mouse died on the twelfth day of infection.
- mice used in these experiments belong to the line C57B1 / 6, which is particularly sensitive to infection by Salmonella (Mastroeni et al, Fund. Clin. ImmunoL, 1994, 2, 83- 95).
- strain S. typhi Ty267 (fusion iagA '-lacZ) was seeded in favorable LB medium and in favorable LB medium containing the fatty acid to be tested, in the form of its sodium salt, at the final concentration of 5 mM.
- the different fatty acids tested are shown in Table VI below:
- the ⁇ -galactosidase activity of the iagA '-lacZ fusion was measured after 6 hours of incubation at 37 ° C. with shaking (200 rpm).
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002413284A CA2413284A1 (fr) | 2000-06-22 | 2001-06-22 | Utilisation d'acides en c4-c10 pour la prevention des infections a bacteries a gram negatif |
EP01947582A EP1292291A2 (fr) | 2000-06-22 | 2001-06-22 | Utilisation d'acides en c 4-c10 pour la prevention des infections a bacteries a gram-negatif |
AU2001269239A AU2001269239A1 (en) | 2000-06-22 | 2001-06-22 | Use of c4-c10 acids for preventing gram-negative bacterial infections |
US10/312,047 US20040116523A1 (en) | 2000-06-22 | 2001-06-22 | Use of c4-c10 acids for preventing gram-negative bacterial infections |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0007992A FR2810546A1 (fr) | 2000-06-22 | 2000-06-22 | Utilisation d'acides en c2-c10 pour la prevention des infections a bacteries a gram negatif |
FR00/07992 | 2000-06-22 | ||
FR0008383A FR2810547B1 (fr) | 2000-06-22 | 2000-06-29 | Utilisation d'acides en c2-c10 pour la prevention des infections a bacteries a gram negatif |
FR00/08383 | 2000-06-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001097791A2 true WO2001097791A2 (fr) | 2001-12-27 |
WO2001097791A3 WO2001097791A3 (fr) | 2002-06-06 |
Family
ID=26212484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/001971 WO2001097791A2 (fr) | 2000-06-22 | 2001-06-22 | Utilisation d'acides en c4-c10 pour la prévention des infections a bactéries a gram négatif |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040116523A1 (fr) |
EP (1) | EP1292291A2 (fr) |
AU (1) | AU2001269239A1 (fr) |
CA (1) | CA2413284A1 (fr) |
FR (1) | FR2810547B1 (fr) |
WO (1) | WO2001097791A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1628622A4 (fr) * | 2003-05-20 | 2008-12-17 | Baylor Res Inst | Acides gras a cinq ou quinze carbones destines a traiter des troubles metaboliques et utilises comme complements nutritionnels |
US7611729B2 (en) | 2001-09-10 | 2009-11-03 | Lunamed Ag | Dosage forms having prolonged active ingredient release |
EP2381797B1 (fr) | 2009-01-23 | 2017-03-08 | Nutreco Nederland B.V. | Additif d'aliment de bétail et aliment de bétail comprenant des esters alcoyls d'acides gras de longueur de chaîne intermédiaire, et leur utilisation dans les aliments de bétail |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101959429B (zh) | 2008-01-08 | 2014-09-10 | 阿克塞利亚制药公司 | 抗微生物肽系统的激动剂 |
US20100249747A1 (en) * | 2009-03-26 | 2010-09-30 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solution |
US9072296B2 (en) | 2009-03-26 | 2015-07-07 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
US9433209B2 (en) | 2009-03-26 | 2016-09-06 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
US9427498B2 (en) | 2009-03-26 | 2016-08-30 | Organic Medical Ventures, L.L.C. | Syringe treated with transdermal venous access locking solutions and method of treating the syringe |
US10772343B2 (en) | 2014-11-19 | 2020-09-15 | Kansas State University Research Foundation | Chemical mitigants in animal feed and feed ingredients |
SE538436C2 (en) * | 2014-12-09 | 2016-06-28 | Perstorp Ab | Composition inhibiting gram-negative pathogens in galloanserans |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2466663A (en) * | 1944-10-20 | 1949-04-05 | Ward Baking Co | Fungicide containing caprylic acid and its salt |
EP0021504A2 (fr) * | 1979-06-25 | 1981-01-07 | THE PROCTER & GAMBLE COMPANY | Article utilisable comme cathéter ou analogue |
US4406884A (en) * | 1981-06-23 | 1983-09-27 | The Procter & Gamble Company | Topical antimicrobial composition |
US4489097A (en) * | 1976-07-28 | 1984-12-18 | The Procter & Gamble Company | Intravenous solutions with antimicrobial agent |
US5234719A (en) * | 1991-06-04 | 1993-08-10 | Ecolab Inc. | Food additive sanitizing compositions |
WO1997000676A1 (fr) * | 1995-06-21 | 1997-01-09 | Oy Extracta Ltd. | Composes antimicrobiens et anti-inflammatoires |
WO1998003066A1 (fr) * | 1996-07-19 | 1998-01-29 | Kemira Chemicals Oy | Composition antimicrobienne et procede de preparation |
US6071961A (en) * | 1995-11-28 | 2000-06-06 | Wider; Michael D. | Antimicrobial composition and methods of use therefor |
WO2001097799A1 (fr) * | 2000-06-20 | 2001-12-27 | Nutrition Sciences | Acides gras a chaines moyennes utilisables comme agents antimicrobiens |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8525061D0 (en) * | 1985-10-10 | 1985-11-13 | Bp Chem Int Ltd | Antimicrobial additives |
JPS6453627A (en) * | 1987-05-29 | 1989-03-01 | Ricoh Kk | Level shifter circuit device |
JP2581716B2 (ja) * | 1987-12-10 | 1997-02-12 | 日宝化学株式会社 | 毒素原性大腸菌症予防治療剤 |
US5434182A (en) * | 1987-12-31 | 1995-07-18 | Isaacs; Charles E. | Antibacterial fatty acid compositions |
FI100376B (fi) * | 1995-02-06 | 1997-11-28 | Kemira Oyj | Uusi säilöntäainekoostumus |
DE19505518A1 (de) * | 1995-02-10 | 1996-08-14 | Ina Dr Levi | Mittel zur Behandlung von Malaria, Hepatitis-B-Infektionen, Krebserkrankungen und systemischen opportunistischen Infektionen |
JPH08325107A (ja) * | 1995-06-01 | 1996-12-10 | Takasago Internatl Corp | 抗菌剤 |
US5965188A (en) * | 1996-07-31 | 1999-10-12 | Anitox Corporation | Anti-bacterial amine derivatives |
JPH11266796A (ja) * | 1998-03-19 | 1999-10-05 | Zenbi Shoji Kk | 抗菌用飼料添加剤及び該抗菌用飼料添加剤を用いた抗菌方法 |
-
2000
- 2000-06-29 FR FR0008383A patent/FR2810547B1/fr not_active Expired - Fee Related
-
2001
- 2001-06-22 EP EP01947582A patent/EP1292291A2/fr not_active Withdrawn
- 2001-06-22 AU AU2001269239A patent/AU2001269239A1/en not_active Abandoned
- 2001-06-22 US US10/312,047 patent/US20040116523A1/en not_active Abandoned
- 2001-06-22 CA CA002413284A patent/CA2413284A1/fr not_active Abandoned
- 2001-06-22 WO PCT/FR2001/001971 patent/WO2001097791A2/fr not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2466663A (en) * | 1944-10-20 | 1949-04-05 | Ward Baking Co | Fungicide containing caprylic acid and its salt |
US4489097A (en) * | 1976-07-28 | 1984-12-18 | The Procter & Gamble Company | Intravenous solutions with antimicrobial agent |
EP0021504A2 (fr) * | 1979-06-25 | 1981-01-07 | THE PROCTER & GAMBLE COMPANY | Article utilisable comme cathéter ou analogue |
US4406884A (en) * | 1981-06-23 | 1983-09-27 | The Procter & Gamble Company | Topical antimicrobial composition |
US5234719A (en) * | 1991-06-04 | 1993-08-10 | Ecolab Inc. | Food additive sanitizing compositions |
WO1997000676A1 (fr) * | 1995-06-21 | 1997-01-09 | Oy Extracta Ltd. | Composes antimicrobiens et anti-inflammatoires |
US6071961A (en) * | 1995-11-28 | 2000-06-06 | Wider; Michael D. | Antimicrobial composition and methods of use therefor |
WO1998003066A1 (fr) * | 1996-07-19 | 1998-01-29 | Kemira Chemicals Oy | Composition antimicrobienne et procede de preparation |
WO2001097799A1 (fr) * | 2000-06-20 | 2001-12-27 | Nutrition Sciences | Acides gras a chaines moyennes utilisables comme agents antimicrobiens |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 198930 Derwent Publications Ltd., London, GB; AN 1989-216462 XP002163939 TAKASHI KATSUO, FUJITA ITSUKI ET AL.: "Preventing and treating agent for enetrotoxigenic escherichia coli disease." & JP 01 153627 A (NIPPO KAGAKU KK), 15 juin 1989 (1989-06-15) & PATENT ABSTRACTS OF JAPAN vol. 013, no. 417 & JP 01 053627 A (NIPPO KAGAKU KK), 15 juin 1989 (1989-06-15) * |
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 04, 30 avril 1997 (1997-04-30) & JP 08 325107 A (TAKASAGO INTERNATL CORP), 10 décembre 1996 (1996-12-10) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7611729B2 (en) | 2001-09-10 | 2009-11-03 | Lunamed Ag | Dosage forms having prolonged active ingredient release |
EP1628622A4 (fr) * | 2003-05-20 | 2008-12-17 | Baylor Res Inst | Acides gras a cinq ou quinze carbones destines a traiter des troubles metaboliques et utilises comme complements nutritionnels |
EP2381797B1 (fr) | 2009-01-23 | 2017-03-08 | Nutreco Nederland B.V. | Additif d'aliment de bétail et aliment de bétail comprenant des esters alcoyls d'acides gras de longueur de chaîne intermédiaire, et leur utilisation dans les aliments de bétail |
EP2381797B2 (fr) † | 2009-01-23 | 2023-05-31 | Nutreco Nederland B.V. | Additif d'aliment de bétail et aliment de bétail comprenant des esters alcoyls d'acides gras de longueur de chaîne intermédiaire, et leur utilisation dans les aliments de bétail |
Also Published As
Publication number | Publication date |
---|---|
EP1292291A2 (fr) | 2003-03-19 |
CA2413284A1 (fr) | 2001-12-27 |
US20040116523A1 (en) | 2004-06-17 |
FR2810547A1 (fr) | 2001-12-28 |
FR2810547B1 (fr) | 2004-01-30 |
AU2001269239A1 (en) | 2002-01-02 |
WO2001097791A3 (fr) | 2002-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4463773B2 (ja) | Helicobacter種による感染症の予防および治療用経口製剤 | |
Austin et al. | Vibrionaceae representatives | |
US20210275605A1 (en) | Compositions comprising bacterial strains | |
JP5518702B2 (ja) | α−ケトグルタレートの新規の医学的用途 | |
Austin et al. | Vibrios | |
EP1292291A2 (fr) | Utilisation d'acides en c 4-c10 pour la prevention des infections a bacteries a gram-negatif | |
JP5647137B2 (ja) | 新規のポリアミノポリケチド抗生物質およびその使用 | |
EP3993815A2 (fr) | Compositions comprenant des souches bactériennes | |
RU2668160C1 (ru) | Антибактериальная композиция, содержащая белок adk в качестве активного ингредиента, для борьбы с карбапенем-резистентными грамотрицательными бактериями | |
JP2022122857A (ja) | 抗生物質として有用なコロルマイシン誘導体 | |
US20230142090A1 (en) | Compositions and methods for inhibiting vibrio infection | |
JP6920199B2 (ja) | 抗微生物剤耐性を回避する抗下痢製剤 | |
US20200330420A1 (en) | Long chain fatty acid formulations and their use in inhibiting salmonella infection | |
FR2810546A1 (fr) | Utilisation d'acides en c2-c10 pour la prevention des infections a bacteries a gram negatif | |
CN114007440B (zh) | 组合物用于预防、治疗或改善胃肠道疾病的用途 | |
JP6355512B2 (ja) | 不活化ワクチン製剤、並びに感染症予防方法 | |
JPWO2018168407A1 (ja) | フタロシンまたはフタロシン誘導体を経由するメナキノン合成経路を備える細菌の増殖抑制用組成物 | |
WO2023026957A1 (fr) | Agent pour la prévention et/ou le traitement d'une infection par porphyromonas gingivalis | |
Liu | The growth response of Campylobacter jejuni to stress catecholamines | |
JP6928225B2 (ja) | 経口ワクチン製剤、並びに感染症予防方法 | |
JP2024041560A (ja) | 4-ヒドロキシ安息香酸デカルボキシラーゼによるフェノール生成の阻害剤 | |
BE505709A (fr) | ||
FR3052065B1 (fr) | Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne | |
JP2012077033A (ja) | ヘリコバクターピロリの運動能阻害剤 | |
JPH08504401A (ja) | 消化管疾患の治療および特に予防用製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001947582 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2413284 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10312047 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001947582 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001947582 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |